 Shares of Immunomedics Inc. gained 6.9 in trading on Monday after the drugmaker said a confirmatory Phase 3 clinical trial of its breast-cancer drug Trodelvy met its primary and secondary endpoints. The Food and Drug Administration in April had approved Trodelvy as a third-line treatment for patients with metastatic triple-negative breast cancer; the latest research supports the accelerated approval that the FDA had previously granted to the drug. We intend to certainly dominate the triple-negative setting that we are now indicated in it, and I think the data and the label should make that very much doable, Immunomedics board chair Behzad Aghazadeh told investors during a call on Monday, according to a FactSet transcript. Immunomedics stock has soared 89.2 since the start of the year. In comparison, the SP; 500 is down 3.1. 